$7.94 Billion is the total value of Baker Brothers Advisors's 110 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 20.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCYC | Buy | Pharmacyclics Inc. | $1,133,974,000 | +31.8% | 9,656,599 | +0.7% | 14.28% | +35.5% |
| SGEN | Buy | Seattle Genetics, Inc. | $835,648,000 | -2.8% | 22,475,729 | +0.0% | 10.52% | -0.0% |
| Salix 2.75% 5/15/15conv bonds | $737,019,000 | +25.8% | 219,440,000 | 0.0% | 9.28% | +29.3% | ||
| GEVA | Synageva Biopharma Corp. | $733,225,000 | -34.4% | 10,660,432 | 0.0% | 9.23% | -32.5% | |
| INCY | Incyte Corp. | $728,175,000 | -13.1% | 14,845,559 | 0.0% | 9.17% | -10.6% | |
| ACAD | Acadia Pharmaceuticals Inc. | $507,121,000 | +9.6% | 20,481,442 | 0.0% | 6.39% | +12.7% | |
| GHDX | Buy | Genomic Health Inc. | $386,590,000 | +3.3% | 13,655,618 | +0.0% | 4.87% | +6.2% |
| Incyte Corporation Notes 1.25% 11/15/2020conv bonds | $334,033,000 | -10.1% | 274,500,000 | 0.0% | 4.21% | -7.6% | ||
| Incyte Corporation Notes 0.375% 11/15/2018conv bonds | $308,103,000 | -10.9% | 259,000,000 | 0.0% | 3.88% | -8.4% | ||
| AVNR | Buy | Avanir Pharmaceuticals | $250,018,000 | +138.9% | 20,974,677 | +13.0% | 3.15% | +145.6% |
| Incyte Corporation Notes 4.75% 10/1/2015conv bonds | $225,284,000 | -13.1% | 40,446,000 | 0.0% | 2.84% | -10.7% | ||
| BMRN | Buy | Biomarin Pharmaceuticals | $171,053,000 | +44.1% | 2,370,464 | +24.2% | 2.15% | +48.1% |
| AVNR | New | Avanir Pharmaceuticals Inc_FLEX C @ 1.0 DEC 14call | $111,525,000 | – | 9,356,200 | +100.0% | 1.40% | – |
| BCRX | Sell | Biocryst Pharmaceuticals Inc. | $104,780,000 | -24.5% | 10,713,686 | -1.6% | 1.32% | -22.4% |
| ANAC | Buy | Anacor Pharmaceuticals | $102,889,000 | +78.7% | 4,204,702 | +29.5% | 1.30% | +83.8% |
| Gilead 1.625% 5/1/16conv bonds | $100,393,000 | +28.1% | 21,500,000 | 0.0% | 1.26% | +31.7% | ||
| XOMA | Buy | Xoma Corp. | $97,131,000 | -8.3% | 23,071,472 | +0.0% | 1.22% | -5.7% |
| Biomarin Pharmaceuticals Notes 1.875% 4/23/2017conv bonds | $81,355,000 | +15.4% | 22,898,000 | 0.0% | 1.02% | +18.6% | ||
| Medivation 2.625% 4/1/17conv bonds | $67,747,000 | +22.5% | 34,720,000 | 0.0% | 0.85% | +25.8% | ||
| DYAX | Buy | Dyax Corp. | $62,317,000 | +14.3% | 6,157,789 | +8.4% | 0.78% | +17.5% |
| New | Acorda Therapeutics Notes 1.75% 6/15/2021conv bonds | $62,050,000 | – | 60,000,000 | +100.0% | 0.78% | – | |
| CERS | Buy | Cerus | $47,880,000 | +12.6% | 11,940,178 | +16.5% | 0.60% | +15.7% |
| VNDA | Vanda Pharmaceuticals, Inc. | $45,383,000 | -35.8% | 4,372,153 | 0.0% | 0.57% | -33.9% | |
| MRTX | Mirati Therapeutics Inc. | $41,675,000 | -12.4% | 2,380,074 | 0.0% | 0.52% | -9.9% | |
| XNPT | Buy | Xenoport | $36,669,000 | +88.2% | 6,815,777 | +69.0% | 0.46% | +93.3% |
| Salix 1.5% 3/15/19conv bonds | $36,237,000 | +23.1% | 15,000,000 | 0.0% | 0.46% | +26.3% | ||
| DSCI | Derma Sciences | $29,464,000 | -27.9% | 3,537,137 | 0.0% | 0.37% | -25.9% | |
| RPRX | Repros Therapeutics | $27,509,000 | -42.8% | 2,778,654 | 0.0% | 0.35% | -41.3% | |
| GILD | Gilead Sciences Inc. | $27,263,000 | +28.4% | 256,108 | 0.0% | 0.34% | +31.9% | |
| ACOR | Sell | Acorda Therapeutics, Inc. | $25,525,000 | -16.4% | 753,391 | -16.9% | 0.32% | -14.2% |
| HALO | Halozyme Therapeutics Inc. | $25,263,000 | -7.9% | 2,776,143 | 0.0% | 0.32% | -5.4% | |
| VSAR | Buy | Versartis Inc. | $23,663,000 | -32.3% | 1,246,089 | +0.0% | 0.30% | -30.4% |
| PGNX | Progenics Pharmaceuticals, Inc. | $23,094,000 | +20.4% | 4,449,797 | 0.0% | 0.29% | +23.8% | |
| CPRX | Buy | Catalyst Pharmaceuticals, Inc. | $22,295,000 | +296.4% | 6,715,462 | +202.1% | 0.28% | +307.2% |
| TGTX | Sell | TG Therapeutics | $21,877,000 | +7.8% | 2,050,313 | -5.1% | 0.28% | +10.8% |
| HRTX | Heron Therapeutics, Inc. | $21,723,000 | -32.4% | 2,607,784 | 0.0% | 0.27% | -30.5% | |
| ARWR | Sell | Arrowhead Research Corp. | $18,179,000 | -11.2% | 1,230,802 | -14.0% | 0.23% | -8.8% |
| MNKKQ | New | Mallinckrodt PUB LTD CO | $18,197,000 | – | 201,856 | +100.0% | 0.23% | – |
| AMBI | Buy | Ambit Biosciences Corp. | $16,837,000 | +225.8% | 1,093,332 | +46.2% | 0.21% | +236.5% |
| INSM | Buy | Insmed Inc. | $14,457,000 | +138.0% | 1,107,850 | +264.4% | 0.18% | +145.9% |
| Biomarin Pharmaceuticals Notes 0.75% 10/15/2018conv bonds | $13,203,000 | +2.4% | 12,500,000 | 0.0% | 0.17% | +5.1% | ||
| AGIO | Sell | Agios Pharmaceuticals | $10,423,000 | +13.8% | 169,893 | -15.0% | 0.13% | +17.0% |
| OMER | Buy | Omeros Corp. | $10,288,000 | -21.6% | 808,775 | +7.3% | 0.13% | -19.3% |
| TKMR | Tekmire Pharmaceuticals Corp. | $10,235,000 | +61.9% | 484,156 | 0.0% | 0.13% | +67.5% | |
| KYTH | Kythera Biopharmaceuticals | $10,197,000 | -14.6% | 311,255 | 0.0% | 0.13% | -12.3% | |
| SGMO | Buy | Sangamo Biosceiences, Inc. | $9,327,000 | +16.8% | 864,856 | +65.4% | 0.12% | +19.4% |
| NBIX | Neurocrine Biosciences, Inc. | $8,690,000 | +5.6% | 554,590 | 0.0% | 0.11% | +7.9% | |
| RARE | Buy | Ultragenyx Pharmaceuticals | $8,490,000 | +89.1% | 150,000 | +50.0% | 0.11% | +94.5% |
| AQXP | Aquinox Pharmaceuticals, Inc. | $8,071,000 | -28.9% | 1,211,851 | 0.0% | 0.10% | -26.6% | |
| THLD | Buy | Threshold Pharma | $7,791,000 | +7.7% | 2,158,141 | +18.2% | 0.10% | +10.1% |
| PRQR | New | ProQR Therapeutics NV | $6,876,000 | – | 400,000 | +100.0% | 0.09% | – |
| QLTI | QLT Inc. | $6,942,000 | -26.9% | 1,535,863 | 0.0% | 0.09% | -25.0% | |
| DSCO | Discovery Laboratories Inc. | $6,720,000 | +3.4% | 3,652,117 | 0.0% | 0.08% | +6.2% | |
| MGNX | Macrogenics, Inc. | $6,519,000 | -3.8% | 311,891 | 0.0% | 0.08% | -1.2% | |
| OSIR | Osiris Therapeutics Inc. | $6,429,000 | -19.4% | 510,606 | 0.0% | 0.08% | -17.3% | |
| AERI | Aerie Pharmaceuticals | $6,194,000 | -16.5% | 299,356 | 0.0% | 0.08% | -14.3% | |
| EPZM | Epizyme Inc. | $5,802,000 | -12.9% | 214,012 | 0.0% | 0.07% | -11.0% | |
| CNCE | Buy | Concert Pharmaceuticals, Inc. | $5,693,000 | +41.3% | 451,496 | +13.2% | 0.07% | +46.9% |
| FOMX | New | Foamix Pharmaceuticals Ltd. | $5,568,000 | – | 1,021,600 | +100.0% | 0.07% | – |
| BLUE | Sell | Bluebird Bio Inc. | $5,382,000 | -29.6% | 150,000 | -24.3% | 0.07% | -27.7% |
| ARRY | Array Biopharma Inc. | $5,119,000 | -21.7% | 1,433,797 | 0.0% | 0.06% | -20.0% | |
| NVAX | Novavax Inc. | $5,101,000 | -9.7% | 1,223,362 | 0.0% | 0.06% | -7.2% | |
| XNCR | Xencor | $5,049,000 | -19.9% | 542,363 | 0.0% | 0.06% | -16.9% | |
| RXDX | Ignyta | $4,602,000 | -11.3% | 571,000 | 0.0% | 0.06% | -9.4% | |
| IRWD | Sell | Ironwood Pharmaceuticals | $4,485,000 | -34.4% | 346,160 | -22.4% | 0.06% | -33.3% |
| ACHN | Achillion | $4,375,000 | +31.9% | 438,337 | 0.0% | 0.06% | +34.1% | |
| INFI | Sell | Infinity Pharmaceuticals Inc. | $4,187,000 | -47.3% | 312,025 | -50.0% | 0.05% | -45.4% |
| STML | Stemline Therapeutics Inc. | $4,220,000 | -15.1% | 338,671 | 0.0% | 0.05% | -13.1% | |
| CLTX | Celsus Therapeuticssponsored adr ne | $4,111,000 | +10.9% | 673,887 | 0.0% | 0.05% | +15.6% | |
| LJPC | Buy | La Jolla Pharmaceuticals, Inc. | $4,052,000 | +99.1% | 421,631 | +90.2% | 0.05% | +104.0% |
| CLDN | New | Celladon Corp | $3,923,000 | – | 375,000 | +100.0% | 0.05% | – |
| ISIS | Isis Pharmaceuticals, Inc. | $3,739,000 | +12.7% | 96,303 | 0.0% | 0.05% | +14.6% | |
| IDRA | Buy | Idera Pharmaceuticals Inc. | $3,708,000 | -20.7% | 1,619,258 | +0.4% | 0.05% | -17.5% |
| BDSI | Sell | BioDelivery Sciences Intl. Inc. | $3,589,000 | -29.4% | 210,021 | -50.1% | 0.04% | -27.4% |
| LGND | Ligand Pharmaceuticals | $3,449,000 | -24.6% | 73,400 | 0.0% | 0.04% | -23.2% | |
| CYTR | Cytrx Corp. | $3,429,000 | -39.2% | 1,350,000 | 0.0% | 0.04% | -37.7% | |
| KPTI | Karyopharm Therapeutics | $3,288,000 | -24.9% | 94,095 | 0.0% | 0.04% | -24.1% | |
| LPCN | Lipocine Inc. | $3,055,000 | +0.2% | 500,000 | 0.0% | 0.04% | +2.7% | |
| ENTA | Enanta Pharmaceuticals | $2,982,000 | -8.1% | 75,357 | 0.0% | 0.04% | -5.0% | |
| FOLD | Amicus Therapeutics | $2,866,000 | +78.1% | 481,697 | 0.0% | 0.04% | +80.0% | |
| ZGNX | Zogenix, Inc. | $2,703,000 | -42.8% | 2,350,400 | 0.0% | 0.03% | -41.4% | |
| SGYPQ | Sell | Synergy Pharmaceuticals | $2,710,000 | -62.1% | 973,245 | -44.6% | 0.03% | -61.4% |
| BOTA | Biota Pharmaceuticals | $2,734,000 | -13.3% | 1,106,910 | 0.0% | 0.03% | -12.8% | |
| AFMD | New | Affimed Therapeutics B.V. | $2,520,000 | – | 400,000 | +100.0% | 0.03% | – |
| SAGE | New | Sage Therapeutics Inc. | $2,363,000 | – | 75,000 | +100.0% | 0.03% | – |
| AUPH | New | Aurinia Pharmaceuticals, Inc. | $2,339,000 | – | 727,669 | +100.0% | 0.03% | – |
| ALDR | Alder Biopharmaceutical Inc. | $1,944,000 | -36.8% | 153,350 | 0.0% | 0.02% | -36.8% | |
| MSTX | New | Mast Therapeutics, Inc. | $1,671,000 | – | 3,000,000 | +100.0% | 0.02% | – |
| OSUR | Orasure Technologies Inc. | $1,694,000 | -16.1% | 234,664 | 0.0% | 0.02% | -16.0% | |
| SNTA | Synta Pharmaceuticals | $1,505,000 | -26.4% | 500,000 | 0.0% | 0.02% | -24.0% | |
| RCPT | Receptos Inc. | $1,484,000 | +45.8% | 23,900 | 0.0% | 0.02% | +58.3% | |
| FMI | Foundation Medicine Inc. | $1,482,000 | -29.7% | 78,162 | 0.0% | 0.02% | -26.9% | |
| OPHT | Ophthotech Corp. | $1,432,000 | -8.0% | 36,776 | 0.0% | 0.02% | -5.3% | |
| MDWD | Mediwound Ltd. | $1,418,000 | -44.6% | 225,000 | 0.0% | 0.02% | -41.9% | |
| SLXP | Salix Pharmaceuticals | $1,347,000 | +26.7% | 8,621 | 0.0% | 0.02% | +30.8% | |
| LOXO | New | Loxo Oncology Inc. | $1,313,000 | – | 100,000 | +100.0% | 0.02% | – |
| MRNS | New | Marinus Pharmaceuticals Inc. | $1,323,000 | – | 204,476 | +100.0% | 0.02% | – |
| RIGL | Rigel Pharmaceuticals | $935,000 | -46.6% | 481,972 | 0.0% | 0.01% | -42.9% | |
| AKAOQ | Achaogen Inc. | $896,000 | -35.8% | 100,000 | 0.0% | 0.01% | -35.3% | |
| ALNY | Alnylam Pharmaceuticals, Inc. | $906,000 | +23.6% | 11,600 | 0.0% | 0.01% | +22.2% | |
| TSRO | Tesaro Inc. | $840,000 | -13.5% | 31,218 | 0.0% | 0.01% | -8.3% | |
| XLRN | Acceleron Pharma Inc. | $870,000 | -11.0% | 28,765 | 0.0% | 0.01% | -8.3% | |
| GERN | Geron Corp. | $805,000 | -37.7% | 402,629 | 0.0% | 0.01% | -37.5% | |
| ZIOP | Ziopharm Oncology Inc. | $646,000 | -34.5% | 244,619 | 0.0% | 0.01% | -33.3% | |
| QURE | Uniquere B.V. | $284,000 | -31.9% | 30,672 | 0.0% | 0.00% | -20.0% | |
| FPRX | Five Prime Therapeutics Inc. | $233,000 | -24.4% | 19,823 | 0.0% | 0.00% | -25.0% | |
| CCXI | Chemocentryx Inc. | $225,000 | -23.2% | 50,000 | 0.0% | 0.00% | -25.0% | |
| CYCCP | Cyclacel Pharmaceuticals Pfd. Conv. Ex 6%pfd conv ex 6% | $103,000 | -4.6% | 13,253 | 0.0% | 0.00% | 0.0% | |
| Exit | Mast Therapeutics, Inc. | $0 | – | -3,000,000 | -100.0% | -0.02% | – | |
| RGDO | Exit | Regado | $0 | – | -400,000 | -100.0% | -0.03% | – |
| GALT | Exit | Galectin Therapeutics Inc. | $0 | – | -300,000 | -100.0% | -0.05% | – |
| AEGR | Exit | Aegerion Pharmaceuticals | $0 | – | -413,922 | -100.0% | -0.16% | – |
| Exit | Salix Pharmaceuticals Ltd Put 115 July 14 | $0 | – | -125,100 | -100.0% | -0.19% | – | |
| CLVS | Exit | Clovis Oncology | $0 | – | -793,221 | -100.0% | -0.40% | – |
| Exit | Intermune Inc Notes 5% 3/1/15conv bonds | $0 | – | -16,860,000 | -100.0% | -0.49% | – | |
| QCOR | Exit | Questcor Pharmaceuticals, Inc. | $0 | – | -500,000 | -100.0% | -0.57% | – |
| Exit | Intermune Inc Notes 2.5% 12/15/17conv bonds | $0 | – | -41,000,000 | -100.0% | -1.73% | – | |
| ITMN | Exit | Intermune Inc. | $0 | – | -4,722,869 | -100.0% | -2.55% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.